Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 5/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703766 | 1.00 | MAPT (0.63) | MAPTGAAHSD17B10KDM4ERAD52 | |
| SCHEMBL6052489 | 0.86 | MAPT (0.50) | MAPTGAAHSD17B10KDM4ERAD52 | |
| SCHEMBL3156791 | 0.84 | MAPT (0.60) | MAPTGAAHSD17B10KDM4ELMNA | |
| SCHEMBL6052447 | 0.83 | ALDH1A1 (0.61) | MAPTGAAHSD17B10KDM4ELMNA | |
| SCHEMBL5793163 | 0.83 | ALDH1A1 (0.61) | MAPTGAAHSD17B10KDM4ELMNA | |
| SCHEMBL15320132 | 0.83 | MAPT (0.59) | MAPTGAAHSD17B10KDM4ERAD52 | |
| SCHEMBL13419452 | 0.81 | KDM4E (0.57) | MAPTGAAHSD17B10KDM4ERAD52 | |
| SCHEMBL22072965 | 0.81 | KDM4E (0.47) | MAPTGAAHSD17B10KDM4ERAD52 | |
| SCHEMBL29990632 | 0.81 | ALDH1A1 (0.65) | MAPTGAAHSD17B10KDM4ERAD52 | |
| SCHEMBL31316966 | 0.80 | MAPT (0.56) | MAPTGAAHSD17B10KDM4ERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4427812-A2 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents of the University of Michigan (US) | 2024-09-11 | — | — | EP | disclosed |
| EP-3934634-B1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | UNIV MICHIGAN REGENTS (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| CN-114901659-A | Fused pyrimidinone compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220162167-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND USE THEREOF AS ANTI-CANCER AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-26 | — | — | US | disclosed |
| EP-3934634-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents Of The University Of Michigan (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113710241-A | Substituted bicyclic and tetracyclic quinones and related methods of use | 密执安大学评议会 | 2021-11-26 | — | — | CN | disclosed |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
| US-7112594-B2 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-26 | — | — | US | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| CN-1230421-C | Amide compound and pharmaceutical use thereof | MITSUBISHI CHEM CORP (JP) | 2005-12-07 | — | — | CN | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1310488-A1 | FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-14 | — | — | EP | disclosed |
| CN-1346348-A | Amide compound and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2002-04-24 | — | — | CN | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | BET1, NFATC1, ARG1 | MAPT 4876/4885GAA 3435/4885HSD17B10 1731/4885 |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | MAPT 3409/4885GAA 3514/4885HSD17B10 3632/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | MAPT 3409/4885GAA 3514/4885HSD17B10 3632/4885 |
| US-20220162167-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND USE THEREOF AS ANTI-CANCER AGENTS | MCL1, NQO1, GLS | MAPT 2167/4885GAA 2416/4885HSD17B10 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.